Accelerating Development of Microbiome-Based Therapies
Our goal is to improve human health by diagnosing, treating, and preventing diseases associated with the human microbiome. Our current target is Inflammatory Bowel Disease, including ulcerative colitis and Crohn’s Disease, that affects an estimated 3.1 million, or 1.3%, of U.S. adults according to the CDC. With additional funding, we can target other microbiome-associated diseases through expansion of our research platform.
We develop non-invasive ways to monitor individuals for signs of disease, and precision methods to manipulate the microbiome to restore health.
We do this by fostering high-risk translational research designed to positively impact patient lives, and collaborating on clinical studies to reveal how the microbiome impacts human physiology, immune system, metabolome, and the course of disease. Supporting all of our efforts is a strong foundation of resources: our Microbial Omics Core Facility, Data Analysis Pipeline, and the Broad Microbiome Strain Library.
Supporting pioneering translational and clinical microbiome research
Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation.
Cell Host Microbe. 2018 Feb 14;23(2):229-240.e5.
Smillie CS, Sauk J, Gevers D, Friedman J, Sung J, Youngster I, Hohmann EL, Staley C, Khoruts A, Sadowsky MJ, Allegretti JR, Smith MB, Xavier RJ, Alm EJ.
Fecal microbiota transplantation (FMT) from healthy donor to patient is a treatment for microbiome-associated diseases. Although the success of FMT requires donor bacteria to engraft in the patient’s gut, the forces governing engraftment in humans are unknown. Here we use an ongoing clinical experiment, the treatment of recurrent Clostridium difficile infection, to uncover the rules of engraftment in humans. We built a statistical model that predicts which bacterial species will engraft in a given host, and developed Strain Finder, a method to infer strain genotypes and track them over time. We find that engraftment can be predicted largely from the abundance and phylogeny of bacteria in the donor and the pre-FMT patient. Furthermore, donor strains within a species engraft in an all-or-nothing manner and previously undetected strains frequently colonize patients receiving FMT. We validated these findings for metabolic syndrome, suggesting that the same principles of engraftment extend to other indications.
Who We Are
Co-Director, Ramnik Xavier, MD, Ph.D.
Dr. Xavier is Chief of the Division of Gastroenterology at Massachusetts General Hospital; Kurt Isselbacher Professor of Medicine, Harvard Medical School; and Senior Associate Member of the Broad Institute. In addition to his duties as a clinical gastroenterologist, he teaches medical students, residents in medicine, and gastroenterology fellows rotating through the Crohn’s Colitis Center at MGH. Dr. Xavier’s research combines basic science with translational approaches to study Crohn’s disease and ulcerative colitis. He directs the Center for the Study of Inflammatory Bowel Disease, a NIH-funded multidisciplinary program established to identify fundamental mechanisms underlying Crohn’s disease and ulcerative colitis, and co-leads an investigation to identify connections between the microbiome and inflammatory bowel disease, a project that is part of the second phase of the Human Microbiome Project (HMP), an NIH initiative first launched in 2008.
Co-Director, Eric Alm, Ph.D.
Dr. Alm is Professor of Biological Engineering at MIT. Dr. Alm’s research uses complementary computational and experimental methods to engineer the human microbiome, including data science, quantitative analysis, and novel molecular techniques. More broadly, the Alm lab emphasizes a systems-level approach to answering questions and solving problems in microbial ecology that have the potential to improve human health, develop sound bioremediation strategies, and uncover the global history of microbes. Dr. Alm also serves on the Board of Directors for the non-profit stool bank, OpenBiome, and clinical-stage biopharmaceutical company Finch Therapeutics.
Assistant Director, Victoria Mountain, Ph.D.
Vicki Mountain is the Assistant Director of the Center for Microbiome Informatics and Therapeutics. Before joining MIT, Dr. Mountain had an extensive career in scientific publishing spanning time as Senior Editor at Cell press, Medical writer at EBSCO Health, as well as an independent publications writer and editor working for the American Chemical Society, Max-Planck Institute, and biotech start-ups. She has a B.Sc. from the University of Glasgow, U.K., and a Ph.D. in Biochemistry from Dartmouth Medical School.
Get Involved By…
Donating! Contact Vicki Mountain at firstname.lastname@example.org to discuss how to support research at The Center for Microbiome Informatics and Therapeutics
Apply for an Award! Researchers are invited to submit a proposal for an Innovation or Pilot Award in response to out Fall 2018 Request for Applications. Details will be announced here in September.
Collaborate! Clinicians can apply for a clinical collaboration by contacting Vicki Mountain at email@example.com for more information. To be considered for collaborative support a clinical study must be based in New England and must have enrolled at least 30% of subjects.